ERBB2 and breast carcinoma: Due to the introduction of numerous targeted anti-HER2 strategies, HER2-positive breast carcinoma, previously considered to be an entity with a particularly poor prognosis, became an easily treatable disease and one of the subtypes with the best clinical outcomes.